कंपनी का अवलोकन
Aditxt, Inc. operates as a commercial-stage entity dedicated to the discovery and development of products within critical health domains, specifically immune health, precision health, population health, women's health, and neurologic health. The corporation utilizes its proprietary technology, AditxtScore, to assist individuals in understanding, managing, and monitoring their immune profiles. This organization functions within the broader Healthcare sector and the specialized Biotechnology industry, positioning itself as a player focused on advancing medical diagnostics and therapeutic solutions. The company's scale is currently defined by a market capitalization of $479,368 and annual revenue of $3,195, with no employee count data available in public records. These valuation and revenue figures indicate that Aditxt, Inc. functions as a micro-cap entity with minimal revenue generation relative to its market valuation, suggesting a company in an early or transitional stage of commercial viability where future product adoption remains a primary variable for potential expansion.
वित्तीय स्वास्थ्य
The company reported total revenue of $3,195 over the trailing twelve-month period, yet it recorded a net income of -$43,101,452 and an EBITDA of -$19,301,452, revealing a significant structural disconnect where operating expenses drastically exceed income generation. The free cash flow stands at -$18,098,088, which indicates a substantial burn rate that constrains the company's financial flexibility and necessitates external capital raising to sustain operations. Analyzing the profitability metrics, the gross margin is 8.4%, suggesting a moderate ability to cover the direct costs of producing goods or services, while the operating margin is an anomalous -1098725.6% and the profit margin is 0.0%, highlighting severe operational inefficiencies or accounting classifications typical of loss-making biotech firms. The balance sheet shows the company holds $3.20M in cash against $3.01M in debt, resulting in a debt-to-equity ratio of 76.04, which reflects a highly leveraged position where equity is minimal relative to obligations. Liquidity is under significant strain, as evidenced by a current ratio of 0.31, indicating that current assets are insufficient to cover current liabilities without immediate refinancing or asset liquidation. Furthermore, the return on equity is -699.1% and the return on assets is -50.3%, metrics that demonstrate management has not yet generated positive returns on the capital deployed or assets held, pointing to a period of heavy investment prior to sustainable profitability.
मूल्यांकन आकलन
Valuation metrics for Aditxt, Inc. present a complex picture, with a trailing P/E ratio listed as N/A due to the absence of net income and a forward P/E of -0.05, which implies negative earnings expectations for the upcoming period. The price-to-book ratio is recorded at -0.00, indicating that the market valuation does not align with the company's tangible book value, a common characteristic for distressed or pre-profitability biotechnology firms. Alternative valuation measures such as the price-to-sales ratio of 150.04 and an EV/EBITDA of 0.07 suggest that the market is pricing the stock based on speculative future potential rather than current earnings or asset backing. The stock has exhibited extreme volatility, trading between a 52-week low of $0.50 and a 52-week high of $3426.16. Given the 52-week high of $3426.16 and low of $0.50, the current price sits significantly closer to the low end of this range, reflecting a substantial correction from its peak. The beta value is 1.40, which signifies that the stock's price volatility is 40% higher than the broader market, making it a high-risk investment for portfolios sensitive to market fluctuations.
Growth & Income
Aditxt, Inc. experienced a revenue growth year-over-year of -86.6%, while earnings growth is N/A due to the lack of prior comparable positive earnings data. The contraction in revenue implies that the company is facing challenges in scaling its commercial operations or maintaining sales momentum in its current market segments. As a non-dividend payer, the company does not distribute a dividend yield or maintains a payout ratio of 0.0%, which indicates that any generated cash or retained earnings are being reinvested into research, development, and operational costs rather than distributed to shareholders. This reinvestment strategy is standard for early-stage biotechnology companies attempting to achieve commercial milestones, though the current negative growth trajectory complicates the sustainability of this approach. Overall, the company's growth and income profile is characterized by significant revenue contraction and a complete reliance on capital markets to fund operations in the absence of dividend income or positive earnings generation.